Skip to content
AnalystLens

Exelixis Annual Report, Year Ended Jan 1, 2016

Filing Date
Filed February 29, 2016
Period End
January 1, 2016
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Dec ’19Dec ’19
  3. Leadership change8-K · May ’22May ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 10-K filed February 29, 2016. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. ("Exelixis") is a biopharmaceutical company focused predominantly on cabozantinib, a multi-receptor tyrosine kinase inhibitor.

Cabozantinib is approved in the United States and European Union for progressive, metastatic medullary thyroid cancer (MTC) under the brand name COMETRIQ, which generated $74.3 milliona in net revenues from commercial launch through December 31, 2015. Total 2015 revenues were $37.2 million, versus a net loss of $169.7 million, and the accumulated deficit reached $1.9 billion. Cash and investments were $253.3 million at December 31, 2015, of which $169.0 million was available for operations, and the company states that current resources should fund operations for at least 12 months following the filing date.

The key near-term catalysts are the NDA for cabozantinib in advanced renal cell carcinoma (RCC), which was granted priority review with a PDUFA action date of June 22, 2016, and the EMA marketing authorization application, which was accepted with accelerated assessment. The METEOR trial showed a 7.4-month median PFS versus 3.8 months for everolimus, and a second interim analysis showed a highly statistically significant overall survival increase. On February 29, 2016, Exelixis entered a collaboration with Ipsen for ex-U.S., Canada and Japan rights, providing a $200.0 millionb upfront payment, with additional regulatory and commercial milestones and tiered royalties.

The company carries significant leverage: total consolidated indebtedness through maturity was $492.5 millionc, including the 4.25% 2019 Notes ($287.5 million principal), Deerfield Notes ($103.8 million outstanding principal), and a $80.0 million Silicon Valley Bank term loan. Investors should weigh the RCC approval and Ipsen payment against continued net losses, debt maturities beginning in 2017, and dependence on partners such as Genentech for cobimetinib (marketed as COTELLIC).

Key Highlights

  1. Cabozantinib NDA for advanced RCC granted priority review by FDA on January 27, 2016, with a PDUFA action date of June 22, 2016
  2. METEOR phase 3 trial: median PFS of 7.4 months for cabozantinib versus 3.8 months for everolimus (HR 0.58); second interim OS analysis showed a highly statistically significant increase
  3. Ipsen collaboration signed February 29, 2016: $200.0 million upfront payment, up to $545.0 million in potential commercial milestones, and tiered royalties of 22% to 26% on ex-U.S., Canada and Japan net sales
  4. 2015 total revenues of $37.2 million and net loss of $169.7 million; accumulated deficit of $1.9 billion
  5. Cash and investments of $253.3 million at December 31, 2015, with $169.0 million available for operations
  6. Total consolidated indebtedness of $492.5 million through maturity, including the 2019 Notes, Deerfield Notes and the Silicon Valley Bank term loan
  7. COTELLIC (cobimetinib, partnered with Genentech) approved by the FDA on November 10, 2015 in combination with vemurafenib for BRAF V600E or V600K mutation-positive advanced melanoma

Financial Statements

FY2016 against FY2015

Line itemFY2016FY2015Change
Revenue$37.17M$37.17M0.0%
Cost of Revenue$3.90M$3.90M0.0%
Gross Profit$33.28M$33.28M0.0%
R&D Expenses$95.97M$96.35M−0.4%
SG&A Expenses$116.14M$57.30M+102.7%
Operating Expenses$219.58M$158.59M+38.5%
Operating Income-$28.12M-$121.42M+76.8%
Interest Expense$33.06M$40.68M−18.7%
Net Income-$70.22M-$161.74M+56.6%
EPS (Basic)$-0.28$-0.77+63.6%
EPS (Diluted)$-0.28——
Shares Outstanding (Basic)250.53M209.23M+19.7%
Shares Outstanding (Diluted)250.53M——

Frequently Asked Questions

  1. What is the most important near-term catalyst for Exelixis?

    The FDA decision on cabozantinib for previously treated advanced RCC, with a PDUFA action date of June 22, 2016. The company states that it is launch-ready from a staffing perspective and that failure to obtain approval would mean it lacks resources to continue its business in its current form.

  2. How much cash does Exelixis have and how long will it last?

    The company had $253.3 million in cash and investments at December 31, 2015, including $169.0 million available for operations, $81.6 million of compensating balance investments held with Silicon Valley Bank, and $2.7 million of long-term restricted investments. It anticipates maintaining operations for at least 12 months following the filing date, but states that it may need to raise additional capital significantly earlier than anticipated.

  3. What are the main debt obligations and their maturities?

    The $80.0 million Silicon Valley Bank term loan is due May 31, 2017. The Deerfield Notes, with $103.8 million outstanding principal at year-end 2015, mature July 1, 2018 and bear 15% total interest. The 4.25% 2019 Notes of $287.5 million mature August 15, 2019, with a conversion price of approximately $5.31 per share.

  4. What does the Ipsen agreement provide?

    Ipsen receives exclusive commercialization rights for cabozantinib outside the United States, Canada and Japan. Exelixis receives a $200.0 million upfront payment, a $60.0 million milestone upon EMA approval in second-line RCC, $10.0 million on filing and $40.0 million on approval in second-line HCC, and royalties of 2% on the first $50 million of net sales, 12% on the next $100 million, then 22% to 26%. Exelixis remains responsible for manufacturing and supply.

  5. What are the key risks highlighted in the filing?

    Key risks include the need for additional capital, a history of net losses with an expected continuation, dependence on regulatory approval for cabozantinib in RCC, competition from nivolumab (approved for RCC on November 23, 2015), reliance on Genentech for cobimetinib and on Ipsen for ex-U.S. development, uncertain results of the CELESTIAL phase 3 trial in HCC expected in 2017, and the prior failure of the COMET-1 and COMET-2 prostate cancer trials.